1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |

---

Santhera Pharmaceuticals ‘s lead drug candidate, Raxone, has been approved by Therapeutic Goods Administration (TGA) as an orphan drug to treat patients with Duchenne Muscular Dystrophy (DMD). Raxone, under the name of Catena, has already received same status b...

Read More

---

First orphan drug approved for Duchenne muscular dystrophy

Release Date: 15 October 2016

Food and drug Association (FDA), U.S, has announced Exondys 51 (eteplirsen) injection as the orphan drug for treatment of patients with Duchenne muscular dystrophy (DMD). Exondys 51 has been developed by Sarepta Therapeutics of Cambridge...

Read More

---

Singh Biotechnology receives orphan drug designation for STAT3

Release Date: 14 October 2016

Food and Drug association, U.S, has granted orphan drug status to SBT-100, developed by Singh Biotechnology, a start-up biotech company. STAT3 has novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single domai...

Read More

---

FDA declares Firdapse as orphan drug for treatment of Myasthenia Gravis

Release Date: 14 October 2016

Catalyst Pharmaceuticals, a company dedicated to drug discovering and developing for patients with rare diseases, announces that orphan drug designation has been granted to Firdapse to treat patients suffering from myasthenia gravis, by ...

Read More

---

Singh Biotechnology receives orphan drug designation for STAT3

Release Date: 14 October 2016

Food and Drug association, U.S, has granted orphan drug status to SBT-100, developed by Singh Biotechnology, a start-up biotech company. STAT3 has novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single domai...

Read More

---

GLPG1690 from Galapogas, receives orphan drug designation for idiopathic pulmonary fibrosis

Release Date: 13 October 2016

Galapogas, a Belgium based drug developing company, has received orphan drug status for GLPG1690 to treat patients suffering from idiopathic pulmonary fibrosis, in Europe. GLPG1690 has unique approach to target a novel molecule, GPR84, a...

Read More

---

FDA grants orphan drug designation to OV101 for Angelman Syndrome

Release Date: 12 October 2016

Ovid therapeutics, a private pharmaceutical company from New York, developed OV101 for the treatment of angelman syndrome. Food and Drug Association, U.S, has approves OV101 as orphan drug designation.

Read More

---

FDA grants orphan drug designation to BIV201 for treatment of Acsites

Release Date: 11 October 2016

BioVie Inc., a company dedicated to discovering and developing therapeutic drugs, declares that it’s new drug candidate BIV201 has received orphan drug designation for the treatment of acsites due to chronic liver cirrhosis....

Read More

---

Orphan drug designation plea for Delta-9-Tetrahydrocannibinol and Cannabidiol

Release Date: 10 October 2016

PhytoPain Pharma Inc., a part of GrowPros Cannabis Ventures Inc., declares the submission of applications for orphan drug designation status for Delta-9-Tetrahydrocannibinol and Cannabidiol for the treatment of Complex Regional Pain Synd...

Read More

---

SB- Fix receives orphan drug designation for Hemophilia B

Release Date: 09 October 2016

FDA announces orphan drug designation status to SB-FIX , zinc finger nuclease (ZFN)-mediated genome editing product for the treatment of hemophilia  from Sangamo Biosciences. The company has aces in therapeutic genome editing.

Read More

---

FDA grants BioXcel’s BXCL101 orphan drug designation for Neurofibromatosis Type 2 (NF2)

Release Date: 08 October 2016

BioXcel, a private pharmaceutical company in Connecticut, declares tht FDA has granted BXCL101, orphan drug designation status for the treatment of the patiets suffering from Neurofibromatosis Type 2, disease associated with neurologic a...

Read More

---

FDA approves Soricimed's SOR-C13 as orphan drug for pancreatic cancer

Release Date: 07 October 2016

Peptide SOR-C13 of Soricimed Biopharma Inc., known for discovering and developing peptide based cancer therapeautics, has been granted as orphan drug designation for the treatment of pancreatic and ovarian cancer by Food and Drug Associa...

Read More

---

Coversin by Akari therapeutics receives Orphan drug Designation from FDA

Release Date: 06 October 2016

Coversin developed by Akari therapeutics, an emerging pharmaceuticals company dedicated to the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases has been granted orphan drug...

Read More

---

FDA approves N-Methanocarbathymidine as orphan drug in U.S

Release Date: 05 October 2016

NandN Pharmaceuticals Inc., an upcoming pharmaceuticals company announces N -Methanocarbathymidine receives orphan drug designation for the treatment of neonatal herpes simplex, by FDA.

 

Read More

---

FDA orphan drug designation for ProTmune given to Fate Therapeutics

Release Date: 04 October 2016

Fate therapeutics receives Orphan drug designation for prevention of graft-versus-host disease in patients undergoing allogeneic hematopoietic cell transplantation and also includes blood cancer and genetic disorders by Food and Drug Ass...

Read More

---

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |